SLC5A2 and hydrops fetalis: We understand that a control group is essential for clinical studies, but SGLT2 inhibitors are now generally recommended in HF patients regardless of T2DM presence, so there was no possibility of creating a control group beyond SGLT2 inhibitor administration.